Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.81B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 1.02M
Average 0.71M
ZYME Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Zymeworks Inc.NASDAQ: ZYME
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of $23.08M rose 234.0% year over year, ahead of the +56.7% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 103.7% from the prior quarter. Over 3 fiscal years it compounded at +91.1% a year.
Context
- Stock-based compensation amounted to 26.5% of revenue in FY2025, up 3.1 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +234.0% holds above the trailing-twelve-month pace of +56.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 28.03M USD
- Year-over-year change
- +57.6%
- 4-year CAGR
- +27.1%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.03M | +57.6% |
| FY2024 | 2024-12-31 | 17.79M | +119.6% |
| FY2023 | 2023-12-31 | 8.1M | +101.8% |
| FY2022 | 2022-12-31 | 4.02M | -62.7% |
| FY2021 | 2021-12-31 | 10.76M | — |
Stock-Based Compensation vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 stock-based compensation of $37.94M is the 3rd largest of the 11 companies compared; the peer median is $14.41M.
- Its year-over-year change of +56.7% is the 3rd highest of 10, against a peer median of +10.2%.
- Stock-based compensation amounts to 14.3% of revenue for ZYME, versus a peer median of 20.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Jun 2026 | $39.03M | +10.2% | -4.0% | 37.2% | |
| LTM Sep 2026 | $37.94M | +56.7% | +91.1% | 14.3% | |
| LTM Sep 2026 | $37.41M | +60.8% | +68.9% | — | |
| LTM Sep 2026 | $36.81M | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $16.18M | +309.7% | +51.1% | 136.2% | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $9.87M | -60.9% | -19.2% | — | |
| LTM Mar 2026 | $9.12M | +17.3% | -21.7% | 25.6% | |
| LTM Dec 2025 | $0 | — | — | 0.0% | |
| Peer median (excluding ZYME) | $14.41M | +10.2% | -7.6% | 20.8% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| Deferred Income Tax | (953K) | 1.94M | (757K) | 691K | 945K |
| Stock-Based Compensation | 10.76M | 4.02M | 8.1M | 17.79M | 28.03M |
| Change in Working Capital | 393K | 4.02M | (25.55M) | (30.95M) | 7.5M |
| Accounts Receivables | (266K) | (17.51M) | 13.92M | (36.36M) | 51.2M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 16.48M | 26.48M | (44.77M) | 14.34M | (23.65M) |
| Other Working Capital | (15.82M) | (4.96M) | 5.3M | (8.93M) | (20.05M) |
| Other Non-Cash Items | (387K) | (2.21M) | 1.27M | 13.93M | 532K |
| Operating Cash Flow | (192.45M) | 144.11M | (118.3M) | (110.04M) | (33.01M) |
| Capital Expenditures | (13.29M) | (13.13M) | (4.08M) | (3.07M) | (1.52M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (35.08M) | (40.72M) | (553.25M) | (283.74M) | (196.06M) |
| Sales of Investments | 192.96M | (40.72M) | 350.07M | 325.57M | 225.08M |
| Other Investing Activities | (881K) | 40.72M | (1.6M) | (1.08M) | 0 |
| Investing Cash Flow | 144.6M | (53.85M) | (207.25M) | 38.76M | 26.66M |
| Debt Repayment | (17K) | (14K) | (21K) | (14K) | 0 |
| Common Stock Issued | 0 | 107.53M | 76.1M | 0 | 23.32M |
| Common Stock Repurchased | 0 | 0 | 0 | (30.05M) | (41.7M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 8.03M | 1.06M | 5.77M | 9.61M | (181K) |
| Financing Cash Flow | 8.01M | 108.58M | 81.85M | (20.45M) | (18.56M) |
| Effect of Forex Changes | (325K) | 203K | 354K | 286K | (45K) |
| Net Change in Cash | (40.17M) | 199.05M | (243.36M) | (91.45M) | (24.95M) |
| Free Cash Flow | (205.74M) | 130.98M | (122.38M) | (113.11M) | (34.53M) |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$26.04
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.